Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.66 |
| ▸ | ITPR3 | Q14573 | 7/20 | 0.55 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.50 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.48 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654572 | 0.93 | ITPR3 (0.59) | GBA1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL8500705 | 0.90 | ITPR3 (0.57) | GBA1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL8496576 | 0.90 | ITPR3 (0.57) | GBA1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL3081758 | 0.90 | LPAR3 (0.55) | GBA1ITPR3LPAR3LPAR1LPAR2 | |
| SCHEMBL3086058 | 0.90 | LPAR3 (0.55) | GBA1ITPR3LPAR3LPAR1LPAR2 | |
| SCHEMBL7751818 | 0.88 | LPAR3 (0.52) | GBA1ITPR3ITPR2ITPR1LPAR3 | |
| SCHEMBL3086336 | 0.88 | LPAR3 (0.52) | GBA1ITPR3ITPR2ITPR1LPAR3 | |
| SCHEMBL3080816 | 0.88 | LPAR3 (0.52) | GBA1ITPR3ITPR2ITPR1LPAR3 | |
| SCHEMBL3645971 | 0.86 | ITPR3 (0.63) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL3073627 | 0.83 | PDPK1 (0.47) | GBA1ITPR3ITPR2ITPR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | GBA1 2176/4885ITPR3 3281/4885ITPR2 3937/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | GBA1 91/4885ITPR3 4534/4885ITPR2 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.